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ABBREVIATIONS 
IQR – interquartile range 
PE – pulmonary embolism 
RCT – randomized clinical trial 
VTE – venous thromboembolism 
 
ESSENTIALS 
 Pulmonary embolism (PE)-related death is often a component of the outcome venous 
thromboembolism. 
 This systematic review summarizes definitions for PE-related death used in recent studies. 
 Only half of the studies reported their definitions for PE-related death, which were 
heterogeneous. 
 PE-related death rates varied widely across studies. A better standardization is needed. 
 
ABSTRACT 
BACKGROUND: Pulmonary embolism (PE)-related death is a component of the primary outcome in 
many venous thromboembolism (VTE) studies. The absence of a standardized definition for PE-
related death hampers study outcome evaluation and between-study comparisons. 
OBJECTIVES: To summarize definitions for PE-related death used in recent VTE studies and to assess 
the PE-related death rate. 
PATIENTS/METHODS: A systematic literature search was conducted on April 26th, 2018 from January 
1st, 2014 up to the search date in MEDLINE, Embase, and CENTRAL. Cohort studies and randomized 
trials in which PE-related death was included in the primary outcome were eligible. Screening of 
titles, abstracts, and full-text articles, and data extraction were independently performed in 
duplicate by two authors. Study outcomes included the definition for PE-related death, VTE case-
fatality rate, and death due to PE rate. Descriptive statistics were used to analyze the data. 
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RESULTS: Of the 6,807 identified citations, 83 studies were included of which 27% were randomized 
trials, 31% were prospective and 42% retrospective cohort studies. Thirty-five studies (42%) had a 
central adjudication committee. Thirty-eight (46%) reported a definition for PE-related death of 
which the most frequently used components were ‘autopsy-confirmed PE’ (50%), ‘objectively 
confirmed PE before death’ (55%), and ‘unexplained death’ (58%). Median VTE case-fatality rate was 
1.8% (interquartile range, 0.0 to 13). 
CONCLUSIONS: Only half of the included studies reported definitions for PE-related death, which 
were very heterogeneous. Case-fatality rate of VTE events varied widely across studies. 
Standardization of the definition and guidance on adjudication and reporting of PE-related death is 
needed. 
 
KEYWORDS 
Pulmonary embolism 
Venous thromboembolism 
Cause of Death 
Mortality 
Outcome Assessment (Health Care) 
 
INTRODUCTION 
Pulmonary embolism (PE)-related death is a component of the primary endpoint in many venous 
thromboembolism (VTE) clinical studies. At present, there is no standardized definition for PE-
related death and the use of different definitions across studies may hamper proper trial outcome 
evaluation and between-study comparisons. In addition, meta-analyses of clinical endpoints 
including PE-related death may be biased as included studies may report over- or underestimated 
risk estimates. Central independent adjudication committees are currently suggested by both the 
Food and Drug Administration and the European Medicine Agency to standardize outcome 
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assessment, thereby minimizing between-study differences [1,2]. However, recent studies indicated 
that commonly used definitions of PE-related death may be non-specific despite central adjudication 
and reproducibility of outcome adjudication for PE-related death appeared to be poor [3,4]. This 
may lead to misclassifications that significantly affect the validity of study results. In this systematic 
review, we aimed to summarize definitions for PE-related death used in recent VTE studies and 
assess the VTE case-fatality rate and death due to PE rate. 
 
METHODS 
Literature search  
A systematic search of literature was conducted in MEDLINE and Embase on April 26th, 2018 from 
January 1st, 2014 up to the search date combining terms for ‘venous thromboembolism’, ‘pulmonary 
embolism’, ‘deep vein thrombosis’, ‘fatal’, and ‘death’ (see Appendix 1 for search strategies). The 
Cochrane Central Register of Controlled Trials (CENTRAL) was searched from March 1st, 2018 up to 
the search date.  
 
Eligibility criteria, study selection, and data extraction 
Cohort studies and randomized clinical trials (RCTs) in which PE-related death was a component of 
the primary endpoint were eligible. Studies that were not restricted to adults, those without original 
data, and conference abstracts were excluded.  
Titles, abstracts, and subsequently full-text articles were independently screened in duplicate by two 
authors (NK and TT) using Covidence systematic review software (Veritas Health Innovation, 
Melbourne, Australia. Available at www.covidence.org). Data extraction was independently 
performed in duplicate by two authors (NK and TT) using standardized forms, including study 
characteristics, definitions for PE-related death, and study outcomes (VTE, PE-related death, and all-
cause mortality). A discussion was held in case of disagreement in order to reach consensus. 
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Study outcomes 
The primary outcome was the definition for PE-related death used in the included studies. 
Secondary outcomes were the case-fatality rate of VTE, defined as the proportion of PE-related 
deaths relative to the total number of VTE events, and the death due to PE rate, defined as the 
proportion of PE-related deaths relative to the total number of deaths. 
Statistical analysis 
Descriptive statistics were used to describe study characteristics and definitions for PE-related 
death. Components of the definitions for PE-related death were reported separately and were 
categorized into subgroups. The frequency of reported components was presented in a histogram. 
For each study, the PE-related death rate, the case-fatality rate of VTE events and the death due to 
PE were computed using reported data on PE-related death, VTE events, and all-cause mortality. In 
subgroup analyses, each outcome was assessed by study design (i.e., RCT, prospective and 
retrospective cohort) and by use of a central outcome adjudication committee. All analyses were 
performed in R (v3.5.1, The R Foundation for Statistical Computing © 2018, www.R-project.org). 
 
RESULTS 
Study characteristics 
Of the 6,807 citations identified in the literature search, 83 studies were found to be eligible (Figure 
1; PRISMA flowchart). Characteristics of the included studies are depicted in Table 1. Median sample 
size was 614 (interquartile range [IQR], 212 to 3,289). Twenty-six studies (31%) were prospective, 35 
(42%) were retrospective, and 22 (27%) were RCTs. Twenty-three studies (28%) assessed VTE 
prediction, 19 (23%) prevention, 16 (19%) treatment, 12 (14%) incidence, 5 (6.0%) etiology, 5 (6.0%) 
were diagnostic studies, and 3 (3.6%) could not be classified into one of these categories. Thirty-five 
studies (42%) had a central adjudication committee which assessed all outcome events occurring 
during the study period. Seventeen of 22 RCTs (77%) reported an adjudication committee. These 
figures were 50% and 14% for prospective and retrospective cohort studies, respectively. 
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Definitions for pulmonary embolism-related death 
Definitions for PE-related death were reported in 38 studies (46%; see Table 2 for the components 
of the definitions; see Appendix 2 for detailed definitions as reported in the original studies). 
Components of the definition for PE-related death were classified into four categories: ‘autopsy-
confirmed PE’, ‘objectively confirmed PE before death’, ‘unexplained death’, and ‘other’ for those 
that did not belong to one of the other categories. Figure 2 depicts the overall frequency of the 
different components as well as the variety of descriptions used to define these components. 
‘Autopsy-confirmed PE’ was a component of PE-related death in 19 of 38 studies (50%); ‘objectively 
confirmed PE before death’ in 21 studies (55%); and ‘unexplained death’ in 22 studies (58%). Fifteen 
studies (39%) reported a definition component classified as ‘other’, including ‘objective 
documentation of PE’ for which it was not specified if it regarded objective testing before death or 
upon autopsy, ‘specific signs or symptoms before death in the absence of other (cardiopulmonary) 
causes of death’, and death in which clinical judgment determined whether it was caused by PE. 
Nine studies (24%) included all three components ‘autopsy-confirmed PE’, ‘objectively confirmed PE 
before death’, and ‘unexplained death’ in the definition of PE-related death. 
 
Study outcomes 
Outcome event rates are detailed in Table 3. Pulmonary embolism-related death rates were not 
reported in 13 studies (16%). The numbers of PE-related deaths objectively confirmed by autopsy or 
before death were not reported or did not occur in any of the studies. Eleven studies (13%) reported 
on the number of ‘unexplained deaths’, accounting for 2.4 to 47% of VTE events. 
Median VTE case-fatality rate, defined as the proportion of PE-related deaths relative to the 
total number of VTE events, was 1.8% (IQR, 0.0 to 13; range, 0.0 to 80; histogram shown in Appendix 
3). Median VTE case-fatality rate was 0.0% (IQR, 0.0 to 7.1) in RCTs, 11% (IQR, 0.0 to 18) in 
prospective cohort studies, and 3.8% (IQR, 1.1 to 11) in retrospective cohort studies, respectively. 
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These figures were 3.6% (IQR, 0.0 to 15) and 1.4% (IQR, 0.0 to 11) in studies with and without an 
adjudication committee, respectively. 
Median proportion of deaths due to PE, defined as the proportion of PE-related deaths relative 
to the total number of deaths, was 8.2% (IQR, 0.0 to 33; range, 0.0 to 100; histogram shown in 
Appendix 4). Median death due to PE rate was 0.0% (IQR, 0.0 to 13) in RCTs, 7.0% (IQR, 0.0 to 26) in 
prospective cohort studies, and 33% (IQR, 7.1 to 71) in retrospective cohort studies, respectively. 
These figures were 6.3% (IQR, 0.0 to 14) and 25.0% (IQR, 1.3 to 67) in studies with and without an 
adjudication committee, respectively. 
 
DISCUSSION 
This systematic review summarizes the definitions for PE-related death reported in recent clinical 
studies in which PE-related death was a component of the primary outcome. Half of the studies did 
not report a definition for PE-related death. Definitions used in the remaining studies were 
heterogeneous, and mostly included the components ‘autopsy-confirmed PE’, ‘objectively confirmed 
PE before death’, or ‘unexplained death’. The VTE case-fatality rate and death due to PE rate varied 
widely among the included studies.  
 Pulmonary embolism-related death is often a component of the outcome (recurrent) VTE in 
clinical studies. It is important to realize that the number of deaths classified as being related to PE 
influences the magnitude of the outcome (recurrent) VTE; studies with higher numbers of PE-related 
deaths will report higher numbers of (recurrent) VTE events. As mortality rate is often at least as 
high as the rate of (recurrent) VTE, a high sensitivity and specificity of the definition for PE-related 
death are crucial to minimize the number of false positive and false negative classifications, which 
could have deleterious consequences for clinical trial results. In trials with a superiority design, 
deaths falsely designated as being PE-related can increase the numbers of patients with (recurrent) 
VTE in both treatment groups, thereby ’diluting’ the relative difference and possibly leading to a 
type II error (failure to reject the null hypothesis when it is false). In those with a non-inferiority 
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design, a smaller relative difference between groups may lead to a type I error (rejection of the null 
hypothesis when it is true). For example, the CATCH trial and Hokusai VTE Cancer trial both 
randomized patients with cancer-associated VTE to two anticoagulant treatment regimens, yet the 
contribution of PE-related deaths to the primary outcome rate differed widely between the two 
trials. In the CATCH study, almost half of recurrent VTE events were PE-related deaths, 17 of 31 
events (55%) in the tinzaparin treatment arm and 17 of 45 (38%) in the warfarin arm [16]. In the 
Hokusai VTE Cancer study, these figures were markedly lower: only 3 of 34 recurrent VTE events 
(8.8%) in the edoxaban group and 3 of 54 events (5.6%) in the dalteparin group werePE-related 
deaths [17]. CATCH, a superiority trial, reported a non-significant difference in recurrent VTE rates 
between both treatment arms (hazard ratio, 0.65; 95% CI, 0.41 to 1.03; P=0.07). Hypothetically, if 
the proportion of PE-related deaths relative to the numbers of recurrent VTE (i.e., the VTE case-
fatality rate) would have been comparable to that of the dalteparin arm in Hokusai VTE Cancer (6%), 
only 15 of 449 patients (3.3%) in the tinzaparin arm would have had recurrent VTE, and 30 of 451 
(6.7%) in the warfarin arm. A simple chi-square test indicates that these recurrent VTE rates would 
have been significantly different (P=0.03). 
The accuracy of the definition for PE-related death is highly dependent on the components 
used to define this outcome. Of the studies that reported a definition for PE-related death, 
approximately one in two studies included ‘autopsy-confirmed PE’, ‘objectively confirmed PE’, or 
‘unexplained death’ as a component of the definition. Only one quarter of these studies included all 
three components. 
Although autopsies are not routinely performed in every deceased patient, it may identify 
undiagnosed PE. Previous autopsy series in various populations reported that PE was found to be the 
cause of death in 2.0 to 11% of autopsies [5–9]. As not every PE found at autopsy implies that the 
patient died from PE, clinical expertise of the pathologist is essential to determine whether the PE 
may have caused the death.  
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Objectively confirmed PE before death was considered in half of the definitions for PE-
related death. Several descriptions were used to define this component with the aim to more clearly 
specify when PE diagnosed before death should also be considered to be the cause of death upon 
adjudication. Some studies added a time frame in which PE had to be diagnosed before death 
ranging between 5 and 30 days, others indicated that PE had to be clinically severe or that another 
cause of death should be absent. Regardless of the description used, clinical judgment remains 
essential to determine whether objectively confirmed PE before death may have substantially 
contributed to the death of the patient. 
Fifty-eight percent of the definitions for PE-related death included unexplained death as a 
component. As defining unexplained death is challenging, a broad variety of descriptions were used 
to define this component, including ‘unexplained’, ‘unexpected’, and ‘sudden’ death, and ‘death for 
which PE cannot be ruled out’. The subjective nature of these descriptions may easily lead to 
misclassification, as previously demonstrated in a study in which the reproducibility of clinical 
outcome adjudication of a VTE prevention trial was assessed [4]. Of the 179 randomly selected 
cases, 27 were suspected VTE events of which 8 were classified as ‘possible fatal PE’ (unexplained 
death) at repeated adjudication. Of those, 4 were classified as ‘other cause of death’ in the original 
trial (50% discordance rate), despite the fact that the same outcome definition (i.e., ‘sudden death 
without an obvious cause’) was used for both adjudication sessions. In contrast to VTE research, 
unexplained deaths in the field of cardiovascular research are regarded as cardiovascular deaths 
instead of PE-related deaths and thereby contribute to the primary outcome in many trials as well 
[10–13]. Interestingly, only 3 to 4% of unexplained deaths are found to be caused by PE in 
unexplained (sudden) death case series [14,15]. Therefore, detailed information on the death 
circumstances and specific criteria are needed to discriminate between PE and other causes of 
death.  
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Rates of PE-related death subcategories were poorly reported or not reported at all. In fact, 
only 1 in 8 studies reported on the number of unexplained deaths, and PE-related deaths objectively 
confirmed by autopsy or before death were not reported in most cases or simply did not occur. To 
facilitate accurate interpretation of study outcomes, reporting on the breakdown of outcome events 
is important as a high proportion of unexplained deaths could indicate a lack of detailed information 
on death events. In the abovementioned CATCH and Hokusai VTE Cancer trials, all PE-related deaths 
were unexplained deaths. Although speculative, one of the reasons for the observed difference in 
the proportions of PE-related deaths could be the amount and quality of clinical information 
available for adjudication of these events as study populations were comparable. 
The case-fatality rate of (recurrent) VTE events and death due to PE rate varied considerably 
across studies and appeared not to be influenced by study design or use of an adjudication 
committee. The most plausible explanation for this is the use of different definitions for PE-related 
death, but differences in study populations, clinical settings, data collection, follow-up durations, 
and expertise of adjudication committee members may also have contributed. 
Surprisingly, less than half of the studies reported to have an adjudication committee. A 
previous systematic review reported that 67% of VTE-related RCTs between 2002 and 2012 had an 
adjudication committee [18]. In the present review of the subsequent years, this proportion 
moderately increased to 77%, indicating that still 23% of RCTs did not have an adjudication 
committee (or did not report on it).  
Strengths of this study include the broad search strategy and eligibility criteria, which 
allowed for assessment of PE-related death across a wide range of study types in VTE, thereby 
representing a comprehensive overview of current practice. The present analysis will be used as the 
basis for future development of a standardized definition for PE-related death as well as quality 
improvement recommendations for adjudication of death events in VTE studies. 
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 Subgroup analyses across different study types could not be performed as the number of 
studies per group was deemed too low, which is a limitation of the study. 
In the absence of a standardized definition for PE-related death, study results may be over- 
or underestimated. As a consequence, internal and external study validity may be affected, and 
between-study comparability of study results may be suboptimal. Besides the use of a standardized 
definition for PE-related death, completeness of reporting is also crucial to accurately interpret study 
results. In particular, the breakdown of PE-related death according to subdefinitions should be 
reported to balance the proportion of patients with objective documentation of PE before death and 
those with unexplained death or insufficient information on death circumstances. In addition, 
systematic use of central independent expert adjudication committees should be advocated to 
harmonize and standardize outcome assessment. A working group from the Scientific and 
Standardization Committee on Predictive and Diagnostic Variables in Thrombotic Disease of the 
International Society on Thrombosis and Haemostasis initiated a project in 2017 with the aim to 
develop a guidance statement for a standardized definition of PE-related death and 
recommendations for adjudication and reporting of the cause of death in VTE studies. Use of the 
proposed standardized definition of PE-related death, adjudication process, and reporting of 
outcomes will be reassessed several years after publication. 
The present systematic review showed that definitions for PE-related death were often not 
reported in recent VTE studies in which PE-related death was a component of the primary outcome. 
Reported definitions in the remaining studies were very heterogeneous, adjudication committees 
were only reported in a selection of studies, and reporting of the breakdown of PE-related death was 
infrequent, thereby necessitating guidance for a standardized definition, adjudication, and reporting 
of PE-related death.  
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TABLES 
Table 1 – Study characteristics 
Study Sample size Design Centers Study type Primary outcome 
Adjudication 
committee 
Abbasi, 2011 [19] 8,826,439 
Retrospective 
cohort 
Multi-center Etiology 
VTE in pregnancy and maternal mortality 
from VTE 
No 
Ageno, 2016 [20] 5,142 
Prospective 
cohort 
Multi-center Treatment 
Symptomatic recurrent VTE, major bleeding, 
all-cause mortality 
Yes 
Al-Hameed, 2014 [21] 147 
Retrospective 
cohort 
Single center Prevention 
VTE prophylaxis and VTE-related in-hospital 
mortality. 
No 
Alatri, 2017 [22] 383 
Prospective 
cohort 
Multi-center Prediction 
Recurrent VTE, fatal VTE, major bleeding, 
and overall mortality. 
No 
Allen, 2015 [23] 5,809 
Retrospective 
cohort 
Multi-center Incidence PE and PE-related mortality No 
Andreozzi, 2015 [24] 617 RCT Multi-center Treatment 
Recurrent VTE and major bleeding and 
clinically relevant non-major bleeding 
Yes 
Apenteng, 2017 [25] 1,011 
Retrospective 
cohort 
Multi-center Incidence VTE Yes 
Assareh, 2014 [26] 4,223,317 
Retrospective 
cohort 
Multi-center Incidence Recurrent VTE and all-cause mortality No 
Bahl, 2014 [27] 3,498 
Retrospective 
cohort 
Single center Prevention VTE and major bleeding No 
Bayley, 2016 [28] 7,983 
Retrospective 
cohort 
Single center Prevention Fatal PE No 
Becattini, 2016 [29] 906 
Prospective 
cohort 
Multi-center Prediction Death and PE-related death No 
Bedayat, 2015 [30] 1,664 
Retrospective 
cohort 
Single center Prediction PE-related mortality Yes 
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Adjudication 
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Blix, 2018 [31] 14,272 
Retrospective 
cohort 
Multi-center Incidence VTE No 
Bogdan, 2014 [32] 312 
Retrospective 
cohort 
Multi-center Incidence 
Recurrent VTE, death from PE and 
improvement in vitals or symptoms at 
discharge 
No 
Bouras, 2015 [33] 159,039 
Retrospective 
cohort 
Multi-center Incidence VTE and VTE-related mortality No 
Bova, 2018 [34] 639 
Prospective 
cohort 
Multi-center Prediction 
PE-related death, hemodynamic collapse, 
and recurrent non-fatal PE 
No 
Büller, 2015 [35] 300 RCT Multi-center Prevention VTE Yes 
Camporese, 2016 [36] 241 RCT Multi-center Prevention 
All-cause mortality, symptomatic VTE, and 
asymptomatic proximal DVT 
No 
Catterick, 2014 [37] - 
Retrospective 
cohort 
Multi-center Other 
VTE, VTE-related mortality, VTE-related 
secondary diagnosis rates, readmission rates 
and mortality rates 
No 
Ciurzynski, 2018 [38] 400 
Retrospective 
cohort 
Single center Prediction PE-related death and/or rescue thrombolysis No 
Cohen, 2016 [39] 7,513 RCT Multi-center Prevention VTE, and major bleeding Yes 
Couturaud, 2015 [40] 371 RCT Multi-center Treatment Recurrent VTE and major bleeding Yes 
Den Exter, 2016 [41] 550 RCT Multi-center Treatment 
PE related mortality, major bleeding related 
mortality, cardiopulmonary resuscitation, 
admission to an Intensive Care Unit, or 
requirement of thrombolytic therapy or 
surgical embolectomy. 
Yes 
Etesamifard, 2016 
[42] 
203 
Retrospective 
cohort 
Single center Prediction 
PE-related death, 30-day complications, and 
all-cause mortality 
No 
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Fernandez, 2015 [43] 1,083 
Retrospective 
cohort 
Single center Prediction 
Death from PE, hemodynamic collapse, or 
recurrent nonfatal PE 
No 
Font, 2014 [44] 138 
Prospective 
cohort 
Single center Treatment All-cause mortality and PE-related mortality Yes 
Freund, 2018 [45] 1,916 RCT Multi-center Diagnosis VTE Yes 
Gaertner, 2017 [46] 499 
Prospective 
cohort 
Single center Treatment 
Recurrent VTE, major and non-major 
clinically relevant bleeding, major adverse 
cardiovascular events and death 
No 
George, 2014 [47] 785 
Retrospective 
cohort 
Single center Prediction PE-related death Yes 
Gladman, 2014 [48] 50 
Prospective 
cohort 
Single center Etiology VTE No 
Hara, 2017 [49] 53 
Retrospective 
cohort 
Single center Treatment Recurrent VTE and VTE-related mortality No 
Horner, 2014 [50] 212 
Prospective 
cohort 
Single center Diagnosis VTE and VTE-related death Yes 
Horner, 2014 [51] 70 RCT Single center Treatment 
Proximal propagation of distal DVT, PE, VTE-
related sudden death or major bleeding 
No 
Im, 2017 [52] 172 
Retrospective 
cohort 
Single center Prediction All-cause mortality and PE-related death No 
Imberti, 2014 [53] 258 RCT Multi-center Prevention 
VTE, major bleeding and clinically relevant 
nonmajor bleeding, and all-cause mortality. 
Yes 
Izumi, 2015 [54] 1,288 
Prospective 
cohort 
Multi-center Incidence VTE No 
Jimenez-Alcazar, 2018 
[55] 
611 
Prospective 
cohort 
Multi-center Prediction Recurrent VTE Yes 
Johansson, 2018 [56] 108,025 
Retrospective 
cohort 
Multi-center Prediction VTE No 
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Kawaguchi, 2017 [57] 295 
Retrospective 
cohort 
Single center Prevention VTE and VTE-related death No 
Kline, 2014 [58] 83 RCT Multi-center Treatment 
Death from PE, circulatory shock, or need for 
intubation. 
Death from hemorrhage, and bleeding. 
No 
Koc, 2016 [59] 138 
Retrospective 
cohort 
Multi-center Prediction PE-related mortality No 
Kolluri, 2016 [60] 78 RCT Single center Prevention VTE and major bleeding No 
Krause, 2016 [61] 212 
Prospective 
cohort 
Multi-center Treatment 
VTE, thrombus progression during 
treatment, VTE-related death, and bleeding 
No 
Kumamaru, 2016 [62] 579 
Retrospective 
cohort 
Single center Prediction PE-related mortality No 
Lankeit, 2014 [63] 688 
Prospective 
cohort 
Multi-center Prediction 
PE-related death and PE-related 
complications 
No 
Lee, 2015 [64] 900 RCT Multi-center Treatment 
VTE, major bleeding, clinically relevant 
nonmajor bleeding, and all-cause mortality 
Yes 
Li, 2015 [65] 71 
Retrospective 
cohort 
Single center Prediction PE-related mortality No 
Marconi, 2016 [66] 471 
Prospective 
cohort 
Single center Treatment Recurrent VTE No 
Migita, 2014 [67] 2,162 
Prospective 
cohort 
Multi-center Prevention VTE No 
Mismetti, 2015 [68] 399 RCT Multi-center Treatment Recurrent PE Yes 
Moores, 2016 [69] 134 
Prospective 
cohort 
Single center Diagnosis VTE Yes 
Mos, 2014 [70] 516 
Prospective 
cohort 
Multi-center Diagnosis Recurrent VTE Yes 
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Nendaz, 2014 [71] 1,478 
Prospective 
cohort 
Multi-center Prediction VTE and VTE-related death Yes 
Obi, 2015 [72] 4,844 
Retrospective 
cohort 
Single center Prediction VTE No 
Ogonda, 2016 [73] 11,459 
Retrospective 
cohort 
Multi-center Prevention Fatal PE No 
Onundarson, 2015 
[74] 
1,156 RCT Single center Other 
Non-fatal and fatal arterial or venous 
thromboembolism 
Yes 
Paczynska, 2016 [75] 76 
Prospective 
cohort 
Single center Prediction PE-related mortality No 
Pruszczyk, 2014 [76] 411 
Prospective 
cohort 
Single center Prediction 
PE-related mortality and rescue 
thrombolysis 
No 
Raskob, 2018 [17] 1,050 RCT Multi-center Treatment Recurrent VTE and major bleeding. Yes 
Ratib, 2016 [77] 3,558,680 
Retrospective 
cohort 
Multi-center Incidence VTE No 
Reitter, 2016 [78] 112 
Prospective 
cohort 
Single center Prediction VTE Yes 
Roy, 2017 [79] 1,081 
Retrospective 
cohort 
Single center Other 
Recurrent VTE, PE-related death, major 
bleeding, and all-cause mortality 
Yes 
Roy, 2016 [80] 15,351 RCT Multi-center Prevention 
VTE, major bleeding, and sudden death with 
no obvious cause 
Yes 
Ryan, 2015 [81] 24 
Retrospective 
cohort 
Single center Prevention VTE No 
Sakai, 2016 [82] 120 RCT Single center Prevention VTE No 
Samama, 2014 [83] 1,349 RCT Multi-center Prevention VTE and death Yes 
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Selby, 2014 [84] 1,200 
Prospective 
cohort 
Multi-center Prevention VTE Yes 
Selby, 2015 [85] 265 RCT Multi-center Prevention VTE Yes 
Shirakawa, 2016 [86] 86,024 
Retrospective 
cohort 
Multi-center Etiology PE-related mortality No 
Suttorp, 2014 [87] 805 
Retrospective 
cohort 
Multi-center Etiology Fatal and non-fatal thrombotic events No 
Tafur, 2017 [88] 7,948 
Prospective 
cohort 
Multi-center Prediction 
Recurrent VTE, major bleeding, and all-cause 
mortality 
No 
Tanaka, 2015 [89] 184 
Retrospective 
cohort 
Multi-center Incidence Maternal-death-related VTE Yes 
Tapson, 2017 [90] 163 
Prospective 
cohort 
Multi-center Prevention Clinically significant PE or fatal PE Yes 
Twig, 2017 [91] 2,294,139 
Retrospective 
cohort 
Multi-center Etiology 
Death attributed to fatal arrhythmias, 
hypertensive heart disease, 
cardiomyopathies, arterial disease, heart 
failure, and pulmonary embolism. 
No 
Van Adrichem, 2017 
[92] 
3,062 RCT Multi-center Prevention VTE Yes 
Van der Hulle, 2017 
[93] 
3,465 
Prospective 
cohort 
Multi-center Diagnosis VTE Yes 
Van Es, 2018 [94] 117 
Prospective 
cohort 
Multi-center Prediction VTE Yes 
Vanni, 2015 [95]  496 
Prospective 
cohort 
Multi-center Prediction 
Composite of PE-related death or non-fatal 
haemodynamic collapse 
Yes 
Wahlsten, 2015 [96] 57,619 
Retrospective 
cohort 
Multi-center Incidence Hospitalization for VTE or death from PE No 
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Walker, 2016 [97] 10,598 
Retrospective 
cohort 
Multi-center Incidence VTE No 
Weitz, 2017 [98] 3,365 RCT Multi-center Treatment Recurrent VTE Yes 
Yamada, 2015 [99] 100 RCT Multi-center Treatment 
Recurrent VTE and asymptomatic 
deterioration 
Yes 
Zahir, 2017 [100] 400 
Retrospective 
cohort 
Single center Incidence VTE No 
 
Abbreviations: DVT: deep vein thrombosis, PE: pulmonary embolism, RCT: randomized clinical trial, VTE: venous thromboembolism 
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Table 2 – Components of the definitions for pulmonary embolism-related death 
Study Components of the definitions for pulmonary embolism-related death 
Abbasi, 2011 [19] - 
Ageno, 2016 [20] - 
Al-Hameed, 2014 [21] - 
Alatri, 2017 [22] Death following VTE for which VTE was judged to be the cause of death 
Allen, 2015 [23] - 
Andreozzi, 2015 [24] Objectively confirmed PE on imaging before death 
Apenteng, 2017 [25] - 
Assareh, 2014 [26] - 
Bahl, 2014 [27] - 
Bayley, 2016 [28] - 
Becattini, 2016 [29] 
 Autopsy-confirmed PE 
 Objectively confirmed PE before death 
 Sudden death in the absence of a more probable cause of death 
Bedayat, 2015 [30] 
 Autopsy-confirmed PE 
 Specific signs or symptoms before death in the absence of other cardiopulmonary diseases 
Blix, 2018 [31] - 
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Study Components of the definitions for pulmonary embolism-related death 
Bogdan, 2014 [32] - 
Bouras, 2015 [33] - 
Bova, 2018 [34] 
 Objective documentation of PE 
 Unexplained death for which PE cannot be ruled out 
Büller, 2015 [35] 
 Autopsy-confirmed PE 
 Objectively confirmed PE before death 
 Unexplained death for which PE cannot be ruled out 
Camporese, 2016 [36] 
 Autopsy-confirmed PE 
 On clinical grounds according to the treating physician’s judgment 
Catterick, 2014 [37] - 
Ciurzynski, 2018 [38] - 
Cohen, 2016 [39] - 
Couturaud, 2015 [40] 
 Autopsy-confirmed PE 
 Objectively confirmed PE on imaging before death 
 Sudden death for which PE cannot be ruled out 
Den Exter, 2016 [41] - 
Etesamifard, 2016 
[42] 
Death occurring within 30 days after PE 
Fernandez, 2015 [43] 
 Objective documentation of PE 
 Unexplained death for which PE cannot be ruled out 
Font, 2014 [44] - 
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Freund, 2018 [45] Sudden death in the absence of another obvious cause of death 
Gaertner, 2017 [46] Other causes of death are excluded and PE cannot be ruled out  
George, 2014 [47] 
 Autopsy-confirmed PE  
 Specific signs or symptoms before death in the absence of other cardiopulmonary diseases 
Gladman, 2014 [48] - 
Hara, 2017 [49] 
 Objective documentation of PE 
 No other documented cause of death and PE cannot be ruled out 
Horner, 2014 [50] - 
Horner, 2014 [51] - 
Im, 2017 [52] Objectively confirmed PE soon before death in the absence of an alternative diagnosis 
Imberti, 2014 [53] - 
Izumi, 2015 [54] - 
Jimenez-Alcazar, 2018 
[55] 
 Autopsy-confirmed PE 
 Objectively confirmed clinically severe PE before death 
 Sudden or unexpected death for which PE cannot be ruled out 
Johansson, 2018 [56] Autopsy-confirmed PE 
Kawaguchi, 2017 [57] - 
Kline, 2014 [58] Death within 5 days of PE 
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Study Components of the definitions for pulmonary embolism-related death 
Koc, 2016 [59] 
 Objectively confirmed PE before death 
 Specific signs or symptoms before death in the absence of an alternative cause of death 
Kolluri, 2016 [60] - 
Krause, 2016 [61] - 
Kumamaru, 2016 [62] 
 Autopsy-confirmed PE 
 Specific signs or symptoms before death in the absence of other cardiopulmonary diseases 
Lankeit, 2014 [63] 
 Autopsy-confirmed PE 
 Objectively confirmed clinically severe PE before death in the absence of an alternative 
diagnosis 
Lee, 2015 [64] 
 Autopsy-confirmed PE 
 Objectively confirmed PE on imaging before death 
 Sudden and unexplained death for which PE cannot be ruled out  
Li, 2015 [65] Objectively confirmed in the 30 days before death in the absence of another cause of death 
Marconi, 2016 [66] - 
Migita, 2014 [67] - 
Mismetti, 2015 [68] 
 Autopsy-confirmed PE 
 Objectively confirmed PE on imaging before death  
 Unexplained death for which PE cannot be ruled out 
Moores, 2016 [69] 
 Autopsy-confirmed PE 
 Objectively confirmed clinically severe PE before death 
 Sudden or unexplained death 
Mos, 2014 [70] 
 Objectively confirmed PE before death 
 Death for which PE cannot be ruled out 
A
cc
ep
te
d
 A
rt
ic
le  
This article is protected by copyright. All rights reserved. 
Study Components of the definitions for pulmonary embolism-related death 
Nendaz, 2014 [71] 
 Autopsy-confirmed PE 
 Objectively confirmed PE on imaging before death 
 Death in which VTE was considered a likely contributor to the fatal outcome 
Obi, 2015 [72] - 
Ogonda, 2016 [73] - 
Onundarson, 2015 
[74] 
- 
Paczynska, 2016 [75] - 
Pruszczyk, 2014 [76] - 
Raskob, 2018 [17] 
 Objective documentation that PE caused the death 
 No other documented cause of death and PE cannot be ruled out 
Ratib, 2016 [77] -  
Reitter, 2016 [78] -  
Roy, 2017 [79] - 
Roy, 2016 [80] - 
Ryan, 2015 [81] - 
Sakai, 2016 [82] - 
Samama, 2014 [83] - 
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Study Components of the definitions for pulmonary embolism-related death 
Selby, 2014 [84] 
 Autopsy-confirmed PE 
 Sudden, unexplained death in patients without an autopsy 
Selby, 2015 [85] 
 Autopsy-confirmed PE 
 Sudden, unexplained death in patients without an autopsy 
Shirakawa, 2016 [86] - 
Suttorp, 2014 [87] - 
Tafur, 2017 [88] Death within 10 days of a VTE event in the absence of an alternative cause of death 
Tanaka, 2015 [89] 
 Autopsy confirmed VTE 
 Objectively confirmed VTE by imaging 
 Death related to VTE based on physician’s judgment 
Tapson, 2017 [90] 
 Death caused by PE 
 Unexpected death within 24 hours of onset of the acute PE event 
Twig, 2017 [91] - 
Van Adrichem, 2017 
[92] 
- 
Van der Hulle, 2017 
[93] 
 Autopsy-confirmed PE 
 Objectively confirmed PE before death 
 Death for which PE cannot be ruled out 
Van Es, 2018 [94] -  
Vanni, 2015 [95]  
 Objective documentation of PE  
 Unexplained death for which PE cannot be ruled out 
Wahlsten, 2015 [96] - 
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Study Components of the definitions for pulmonary embolism-related death 
Walker, 2016 [97] - 
Weitz, 2017 [98] 
 Autopsy-confirmed PE 
 Objectively confirmed PE before death 
 Unexplained death for which PE cannot be ruled out 
Yamada, 2015 [99] 
 Objective documentation of PE  
 Unexplained death for which PE cannot be ruled out 
Zahir, 2017 [100] 
 Fatal PE as judged by the primary physician 
 Sudden or unexplained death in the presence of specific signs or symptoms  
 
Abbreviations: PE: pulmonary embolism, VTE: venous thromboembolism. 
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Table 3 – Outcome event rates reported in the included studies 
Study Sample size, n (Recurrent) VTE, n All-cause mortality, n  PE-related death, n  
Case-fatality rate 
VTE events* (%) 
Death due to PE 
rate** (%) 
Abbasi, 2011 [19] 8,826,439 14,741 746 61 0.41 8.2 
Ageno, 2016 [20] 5,142 92 100 10 11 10 
Al-Hameed, 2014 [21] 147 147 16 16 11 100 
Alatri, 2017 [22] 383 - - - - - 
Allen, 2015 [23] 5,809 112 3 2 1.8 67 
Andreozzi, 2015 [24] 617 45 4 1 2.2 25 
Apenteng, 2017 [25] 1,011 21 246 3 14 1.2 
Assareh, 2014 [26] 4,223,317 8,451 - 673 8.0 - 
Bahl, 2014 [27] 3,498 45 - - - - 
Bayley, 2016 [28] 7,983 N/A - 6 N/A - 
Becattini, 2016 [29] 906 N/A 65 37 N/A 57 
Bedayat, 2015 [30] 1,664 N/A 327 109 N/A 33 
Blix, 2018 [31] 14,272 2,444 - - - - 
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Study Sample size, n (Recurrent) VTE, n All-cause mortality, n  PE-related death, n  
Case-fatality rate 
VTE events* (%) 
Death due to PE 
rate** (%) 
Bogdan, 2014 [32] 312 15 - 12 80 - 
Bouras, 2015 [33] 159,039 981 2,426 116 12 4.8 
Bova, 2018 [34] 639 N/A 34 9 N/A 26 
Büller, 2015 [35] 300 60 0 0 0 0 
Camporese, 2016 [36] 241 10 0 0 0 0 
Catterick, 2014 [37] - - - - - - 
Ciurzynski, 2018 [38] 400 N/A 15 6 N/A 40 
Cohen, 2016 [39] 7,513 388 425 41 11 9.7 
Couturaud, 2015 [40] 371 28 19 0 0 0 
Den Exter, 2016 [41] 550 5 7 1 20 14 
Etesamifard, 2016 [42] 203 N/A 11 9 N/A 82 
Fernandez, 2015 [43] 1,083 N/A 176 44 N/A 25 
Font, 2014 [44] 138 N/A 32 5 N/A 16 
Freund, 2018 [45] 1,916 41 5 0 0 0 
A
cc
ep
te
d
 A
rt
ic
le  
This article is protected by copyright. All rights reserved. 
Study Sample size, n (Recurrent) VTE, n All-cause mortality, n  PE-related death, n  
Case-fatality rate 
VTE events* (%) 
Death due to PE 
rate** (%) 
Gaertner, 2017 [46] 499 15 24 5 33 21 
George, 2014 [47] 785 N/A 104 36 N/A 35 
Gladman, 2014 [48] 50 4 15 0 0 0 
Hara, 2017 [49] 53 0 12 0 0 0 
Horner, 2014 [50] 212 1 1 0 0 0 
Horner, 2014 [51] 70 1 0 0 0 0 
Im, 2017 [52] 172 N/A 27 23 N/A 85 
Imberti, 2014 [53] 258 3 0 0 0 0 
Izumi, 2015 [54] 1,288 312 0 - - - 
Jimenez-Alcazar, 2018 
[55] 
611 70 129 9 13 7.0 
Johansson, 2018 [56] 108,025 2,054 - - - - 
Kawaguchi, 2017 [57] 295 0 0 - - - 
Kline, 2014 [58] 83 N/A 2 1 N/A 50 
Koc, 2016 [59] 138 N/A 34 26 N/A 76 
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Study Sample size, n (Recurrent) VTE, n All-cause mortality, n  PE-related death, n  
Case-fatality rate 
VTE events* (%) 
Death due to PE 
rate** (%) 
Kolluri, 2016 [60] 78 2 0 0 0 0 
Krause, 2016 [61] 212 2 - 0 0 - 
Kumamaru, 2016 [62] 579 N/A - 6 N/A - 
Lankeit, 2014 [63] 688 N/A 29 18 N/A 62 
Lee, 2015 [64] 900 76 288 34 45 12 
Li, 2015 [65] 71 N/A 7 5 N/A 71 
Marconi, 2016 [66] 471 34 109 13 38 12 
Migita, 2014 [67] 2,162 314 0 0 0 0 
Mismetti, 2015 [68] 399 14 36 9 64 25 
Moores, 2016 [69] 134 2 5 0 0 0 
Mos, 2014 [70] 516 8 22 1 13 4.6 
Nendaz, 2014 [71] 1,478 30 - 18 60 - 
Obi, 2015 [72] 4,844 387 - - - - 
Ogonda, 2016 [73] 11,459 151 45 8 5.3 18 
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Study Sample size, n (Recurrent) VTE, n All-cause mortality, n  PE-related death, n  
Case-fatality rate 
VTE events* (%) 
Death due to PE 
rate** (%) 
Onundarson, 2015 [74] 1,156 29 28 - - - 
Paczynska, 2016 [75] 76 N/A 10 8 N/A 80 
Pruszczyk, 2014 [76] 411 N/A 21 14 N/A 67 
Raskob, 2018 [17] 1,050 100 398 6 6.0 1.5 
Ratib, 2016 [77] 3,558,680 108,770 - - - - 
Reitter, 2016 [78] 112 14 22 0 0 0 
Roy, 2017 [79] 1,081 - - - - - 
Roy, 2016 [80] 15,351 278 1704 139 50 8.2 
Ryan, 2015 [81] 24 2 - 0 0 - 
Sakai, 2016 [82] 120 29 - 0 0 - 
Samama, 2014 [83] 1,349 63 1 0 0 0 
Selby, 2014 [84] 1,200 7 - 0 0 - 
Selby, 2015 [85] 265 5 - 0 0 - 
Shirakawa, 2016 [86] 86,024 N/A - 59 N/A - 
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Study Sample size, n (Recurrent) VTE, n All-cause mortality, n  PE-related death, n  
Case-fatality rate 
VTE events* (%) 
Death due to PE 
rate** (%) 
Suttorp, 2014 [87] 805 13 - - - - 
Tafur, 2017 [88] 7,948 418 2,229 54 13 2.4 
Tanaka, 2015 [89] 184 N/A 184 13 N/A 7.1 
Tapson, 2017 [90] 163 0 25 0 0 0 
Twig, 2017 [91] 2,294,139 N/A 32,127 70 N/A 0.22 
Van Adrichem, 2017 
[92] 
3,062 31 1 0 0 0 
Van der Hulle, 2017 
[93] 
3,465 18 98 6 33 6.1 
Van Es, 2018 [94] 117 11 31 2 18 6.5 
Vanni, 2015 [95]  496 N/A 27 12 N/A 44 
Wahlsten, 2015 [96] 57,619 594 - 8 1.4 - 
Walker, 2016 [97] 10,598 364 - - - - 
Weitz, 2017 [98] 3,365 80 17 4 5.0 24 
Yamada, 2015 [99] 100 1 3 0 0 0 
Zahir, 2017 [100] 400 42 - 1 2.4 - 
Abbreviations: N/A: not applicable, PE: pulmonary embolism, VTE: venous thromboembolism. 
* The case-fatality rate is the proportion of (recurrent) venous thromboembolic events that were fatal. 
** The death due to PE rate is the proportion of deaths that were attributable to PE. 
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FIGURES 
Figure 1 – PRISMA flowchart 
 
 
Shown is the PRISMA flowchart indicating the process for the selection of eligible studies.
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Figure 2 – Frequencies of the components included in the definitions for pulmonary embolism-
related death 
 
 
 
Shown are the frequencies of the components used to define PE-related death in the included 
studies. Components were classified into four categories: ‘Autopsy-confirmed PE’ (n=19), 
‘Objectively confirmed PE before death’ (n=21), ‘Unexplained death’ (n=22), and ‘Other’ (n=15). For 
each category, the bar at the top represents the total number of studies that included the 
component subgroup in the definition for PE-related death. The bars below indicate the frequencies 
for each of the variations used to describe that component subgroup. 
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APPENDICES 
Appendix 1 -  Electronic search strategies 
Database: Ovid MEDLINE(R) ALL <1946 to April 26, 2018> 
Search Strategy: 
-------------------------------------------------------------------------------- 
1     venous thromboembolism/ or venous thromboembolism.tw. (18655) 
2     Venous Thrombosis/ or ((venous or vein) adj3 thrombo*).tw. (68083) 
3     Pulmonary Embolism/ or ((pulmonary or lung) adj3 emboli*).tw. (50001) 
4     or/1-3 (104458) 
5     FATAL OUTCOME/ (58610) 
6     (fatal or death).tw. (692884) 
7     MORTALITY/ (39556) 
8     mortality.tw,kw. (642835) 
9     or/5-8 (1266725) 
10     4 and 9 (17568) 
11     cohort studies/ or prospective studies/ or retrospective studies/ (1272010) 
12     (cohort or prospective* or retrospective*).tw. (1382200) 
13     randomized controlled trial.pt. (459658) 
14     controlled clinical trial.pt. (92364) 
15     randomi?ed.ab. (490388) 
16     placebo.ab. (188521) 
17     clinical trials as topic.sh. (183424) 
18     randomly.ab. (289382) 
19     trial.ti. (181508) 
20     or/11-19 (2780663) 
21     10 and 20 (7153) 
22     *venous thromboembolism/ or venous thromboembolism.ti. (11211) 
23     *Venous Thrombosis/ or ((venous or vein) and thrombo*).ti. (39179) 
24     *Pulmonary Embolism/ or ((pulmonary or lung) and (emboli* or thrombo*)).ti. (31195) 
25     or/22-24 (68058) 
26     randomized controlled trial.pt. (459658) 
27     controlled clinical trial.pt. (92364) 
28     randomi?ed.ab. (490388) 
29     or/26-28 (786502) 
30     25 and 29 (3703) 
31     21 or 30 (9923) 
32     limit 31 to yr="2014 -Current" (3027) 
33     (child/ or infant/) not adult/ (1254860) 
34     32 not 33 (2979)
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Database: Embase Classic+Embase <1947 to 2018 April 26> 
Search Strategy: 
-------------------------------------------------------------------------------- 
1     *deep vein thrombosis/ (15211) 
2     *lung embolism/ (33096) 
3     *vein thrombosis/ (15101) 
4     *thromboembolism/ (20077) 
5     *venous thromboembolism/ (13410) 
6     ((venous or vein) and thrombo*).ti. (45763) 
7     ((pulmonary or lung) and (emboli* or thrombo*)).ti. (30580) 
8     1 or 2 or 3 or 4 or 5 or 6 or 7 (108006) 
9     *fatality/ or *mortality/ (87735) 
10     (fatal* or death or mortality).tw. (1799286) 
11     9 or 10 (1810431) 
12     8 and 11 (17313) 
13     *cohort analysis/ (17553) 
14     *retrospective study/ (12595) 
15     *prospective study/ (14202) 
16     (cohort or prospective* or retrospective*).tw. (2168890) 
17     major clinical study/ (3093727) 
18     random:.tw. (1307150) 
19     placebo:.mp. (422474) 
20     double-blind:.tw. (192222) 
21     or/13-20 (5496658) 
22     12 and 21 (8974) 
23     *venous thromboembolism/ or *vein thrombosis/ or ((venous or vein) adj3 thrombo*).ti. (51878) 
24     *lung embolism/ or ((pulmonary or lung) adj3 emboli*).ti. (34887) 
25     23 or 24 (82629) 
26     random:.tw. (1307150) 
27     placebo:.mp. (422474) 
28     double-blind:.tw. (192222) 
29     26 or 27 or 28 (1559424) 
30     25 and 29 (5943) 
31     22 or 30 (13151) 
32     limit 31 to yr="2014 -Current" (4533) 
33     (exp infant/ or exp child/ or adolescent/) not exp adult/ (2229776) 
34     32 not 33 (4440) 
35     limit 34 to (conference abstract or conference paper) (1903) 
36     34 not 35 (2537)
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Database: EBM Reviews - Cochrane Central Register of Controlled Trials <March 2018> 
Search Strategy: 
-------------------------------------------------------------------------------- 
1     venous thromboembolism/ or venous thromboembolism.tw. (2016) 
2     Venous Thrombosis/ or ((venous or vein) adj3 thrombo*).tw. (6106) 
3     Pulmonary Embolism/ or ((pulmonary or lung) adj3 emboli*).tw. (2410) 
4     or/1-3 (7177) 
5     FATAL OUTCOME/ (12) 
6     (fatal or death).tw. (33725) 
7     MORTALITY/ (430) 
8     mortality.tw,kw. (42003) 
9     or/5-8 (65892) 
10     4 and 9 (1346) 
11     *venous thromboembolism/ or venous thromboembolism.ti. (1162) 
12     *Venous Thrombosis/ or ((venous or vein) and thrombo*).ti. (3522) 
13     *Pulmonary Embolism/ or ((pulmonary or lung) and (emboli* or thrombo*)).ti. (814) 
14     or/11-13 (4255) 
15     10 or 14 (4953) 
16     limit 15 to yr="2014 -Current" (1291)
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Appendix 2 – Definitions for pulmonary embolism-related death as reported in the original studies 
Study Definition PE-related death 
Abbasi, 2011 - 
Ageno, 2016 - 
Al-Hameed, 2014 - 
Alatri, 2017 
Death following VTE in which VTE was considered a likely contributor to the fatal 
outcome.  
Allen, 2015 - 
Andreozzi, 2015 Fatal PE objectively confirmed by computed tomography or lung scanning. 
Apenteng, 2017 - 
Assareh, 2014 - 
Bahl, 2014 - 
Bayley, 2016 - 
Becattini, 2016 
PE was considered the cause of death based on the autopsy or objective testing 
performed before death or in case of sudden death that could not be explained by a 
more compelling alternative diagnosis. 
Bedayat, 2015 
Death was considered PE-related when (1) either the autopsy data, death certificate, or 
death report on the electronic medical record identified PE-related death or (2) acute 
respiratory failure, cardiopulmonary arrest, or shock was the cause of death, in the 
absence of other cardiopulmonary diseases.  
Blix, 2018 - 
Bogdan, 2014 - 
Bouras, 2015 - 
Bova, 2018 
PE was considered the cause of death if there was objective documentation or in case of 
unexplained death and PE not confidently ruled out. 
Büller, 2015 
PE based on objective diagnostic testing, autopsy, or death which cannot be attributed to 
a documented cause and for which PE/DVT cannot be ruled out (unexplained death). 
Camporese, 2016 
Fatal PE was diagnosed by autopsy, or on clinical grounds according to the treating 
physician judgment. 
Catterick, 2014 - 
Ciurzynski, 2018 - 
Cohen, 2016 - 
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Study Definition PE-related death 
Couturaud, 2015 
Recurrent VTE was defined as fatal in cases of death caused by VTE diagnosed according 
to the above criteria: objectively confirmed on imaging, autopsy confirmed or sudden 
death for which no other cause could be identified (recurrent pulmonary embolism could 
not be ruled out by the Critical Events Committee). 
Den Exter, 2016 - 
Etesamifard, 2016 PE-related death (death occurring within 30 days after presentation). 
Fernandez, 2015 
PE was considered the cause of death if there was objective documentation or the cause 
was unexplained and PE could not be confidently ruled out. 
Font, 2014 - 
Freund, 2018 
A sudden death in the absence of another obvious cause will be adjudicated as related to 
a PE. 
Gaertner, 2017 
Recurrent VTE was considered as the cause of death when other causes were excluded 
and when PE could not be ruled out. 
George, 2014 
A subject was considered to have died of PE-related causes if (a) the autopsy report, 
death certificate, or electronic medical record stated PE as a cause of death, or (b) 
respiratory failure, cardiopulmonary arrest, or shock was the immediate cause of death 
in the absence of other cardiopulmonary diseases or precipitating factors. 
Gladman, 2014 - 
Hara, 2017 
PE was considered the cause of death if there was objective documentation or if death 
could not be attributed to any other documented cause and PE could not be excluded.  
Horner, 2014 - 
Horner, 2014 (RCT) - 
Im, 2017 
PE-related death was defined as death soon after objective confirmation of symptomatic 
PE in the absence of any alternative diagnosis. 
Imberti, 2014 - 
Izumi, 2015 - 
Jimenez-Alcazar, 
2018 
Death was PE-related if PE was confirmed by autopsy, or if death followed a clinically 
severe PE, either initially or after an objectively confirmed recurrent event. Death in a 
patient who died suddenly or unexpectedly was classified as possibly PE-related. 
Johansson, 2018 
Participants who had a VTE event registered as the main cause of death and who 
underwent autopsy were regarded as having a verified VTE. 
Kawaguchi, 2017 - 
Kline, 2014 Death within 5 days of PE. 
Koc, 2016 
PE-related mortality was diagnosed when haemodynamic instability and/or shock 
preceded death, or when a patient experienced pulmonary embolism recurrence.  
When an evident alternative cause of death was reported, such as severe bleeding, 
neoplasm or sepsis with no data for PE-related death, a non-PE death was diagnosed and 
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Study Definition PE-related death 
this contributed to 30-day all-cause mortality. 
Kolluri, 2016 - 
Krause, 2016 - 
Kumamaru, 2016 
Death was considered as PE-related by consensus of three physicians, when (1) either the 
autopsy data, death certification, or death report on the electronic medical record stated 
that the death was caused by PE; or (2) acute respiratory failure, cardiopulmonary arrest 
or shock was the cause of death, in the absence of other cardiopulmonary disease. 
Lankeit, 2014 
Death was determined to be related to PE if it was confirmed by autopsy, or if it followed 
a clinically severe PE episode, either immediately or shortly after an objectively 
confirmed recurrent event, and in the absence of an alternative diagnosis. 
Lee, 2015 
Fatal PE was defined as proven on objective imaging, autopsy, or as the most probable 
cause of a sudden and unexplained death according to central adjudication. 
Li, 2015 
A patient was considered to have died from PE if death occurred within 30 days of PE 
diagnosis and was not attributed to a specific cause aside from PE. 
Marconi, 2016 - 
Migita, 2014 - 
Mismetti, 2015 
PE-related death was not explicitly defined. However, it was included in the definition of 
recurrent PE:  
Symptomatic PE recurrence confirmed by lung scan and/or spiral CT scan and/or 
pulmonary angiography, fatal PE confirmed at autopsy, or unexplained death for which a 
causative role of PE cannot be ruled out. 
Moores, 2016 
Fatal PE was classified as definitely present if PE was confirmed by autopsy, or if death 
followed a clinically severe PE. Fatal PE was classified as possibly present in patients who 
died suddenly or unexpectedly.  
Mos, 2014 
Death was classified as due to PE in case of objective confirmation of PE prior to death or 
if PE could not be confidently excluded as the cause of death. 
Nendaz, 2014 
Death following VTE, confirmed by autopsy or an imaging test, or death in which VTE was 
considered a likely contributor to the fatal outcome. 
Obi, 2015 - 
Ogonda, 2016 - 
Onundarson, 2015 - 
Paczynska, 2016 - 
Pruszczyk, 2014 - 
Raskob, 2018 
PE was considered to be the cause of death if there was objective documentation that 
pulmonary embolism caused the death or if the death could not be attributed to a 
documented cause and pulmonary embolism could not be ruled out. 
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Study Definition PE-related death 
Ratib, 2016 - 
Reitter, 2016 - 
Roy, 2017 - 
Roy, 2016 - 
Ryan, 2015 - 
Sakai, 2016 - 
Samama, 2014 - 
Selby, 2014 
Fatal PE was defined as autopsy-proven pulmonary embolism; possible fatal PE was 
defined as an otherwise unexplained sudden death of a patient without an autopsy. 
Selby, 2015 
Fatal PE was defined as autopsy-proven PE; possible fatal PE was defined as otherwise 
unexplained, sudden death in patients without an autopsy.  
Shirakawa, 2016 - 
Suttorp, 2014 - 
Tafur, 2017 
Fatal VTE was defined as any death occurring within 10 days of a corresponding event, in 
the absence of an alternative cause of death. 
Tanaka, 2015 
Maternal-death-related VTE was defined as VTE demonstrated by contrast enhanced 
computed tomography, pulmonary arteriography, lung scintigraphy, ultrasound 
sonography, autopsy imaging, and/or autopsy, and either a number of expert 
obstetricians in the Maternal Death Exploratory Committee (2010–2013) or Nagaya’s 
group (1991–1992) judging VTE as the cause of death. 
Tapson, 2017 
Fatal PE was defined as death caused by PE or unexpected death within 24 hours of onset 
of the acute event.  
Twig, 2017 - 
Van Adrichem, 2017 - 
Van der Hulle, 2017 
Deaths were classified as caused by PE if it was confirmed by autopsy, was shown by 
objective testing before death, or could not be confidently excluded as a cause of death. 
Van Es, 2018 - 
Vanni, 2015 
PE was considered the cause of death if there was objective documentation or if the 
cause was unexplained and PE could not be confidently ruled out.  
Wahlsten, 2015 - 
Walker, 2016 - 
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Study Definition PE-related death 
Weitz, 2017 
Fatal PE based on autopsy or objective diagnostic testing prior to death. 
Death that could not be attributed to a documented cause and for which PE/DVT could 
not be ruled out (unexplained death). 
Yamada, 2015 
PE was considered as the cause of death if there was objective documentation, or if 
death could not be attributed to a documented cause and PE could not be ruled out. 
Zahir, 2017 
Cause of death/morbidity defined as PE by primary physician and for patients who 
develop signs and symptoms of VTE but died before diagnostic criteria could be met, 
sudden, otherwise unexplained death was taken as a VTE event in the presence of severe 
hypoxia on arterial blood gases and no acute change in chest X-ray. 
 
Abbreviations: DVT: deep vein thrombosis, PE: pulmonary embolism, VTE: venous 
thromboembolism.
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Appendix 3 – Case-fatality rate of venous thromboembolism 
 
 
Shown are the frequencies of the case-fatality rates of venous thromboembolism reported in the 
included studies, defined as the proportion of venous thromboembolic events that were fatal. 
Median case-fatality rate of venous thromboembolism was 1.8% (IQR, 0.0 to 13).
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Appendix 4 – Death due to pulmonary embolism rate 
 
 
Shown are the frequencies of the death due to pulmonary embolism rates reported in the included 
studies, defined as the proportion of death events that were attributable to pulmonary embolism. 
Median death due to pulmonary embolism rate was 8.2% (IQR, 0.0 to 33). 
 
